Terms: = Leukemia AND U2AF1, ENSG00000160201, 7307, Q01081, U2AFBP, U2AF35, RNU2AF1, RN, FP793, DKFZp313J1712 AND Clinical Outcome
4 results:
1. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
Ozga M; Nicolet D; Mrózek K; Yilmaz AS; Kohlschmidt J; Larkin KT; Blachly JS; Oakes CC; Buss J; Walker CJ; Orwick S; Jurinovic V; Rothenberg-Thurley M; Dufour A; Schneider S; Sauerland MC; Görlich D; Krug U; Berdel WE; Woermann BJ; Hiddemann W; Braess J; Subklewe M; Spiekermann K; Carroll AJ; Blum WG; Powell BL; Kolitz JE; Moore JO; Mayer RJ; Larson RA; Uy GL; Stock W; Metzeler KH; Grimes HL; Byrd JC; Salomonis N; Herold T; Mims AS; Eisfeld AK
Leukemia; 2024 Jan; 38(1):45-57. PubMed ID: 38017103
[TBL] [Abstract] [Full Text] [Related]
2. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
Onecha E; Rapado I; Luz Morales M; Carreño-Tarragona G; Martinez-Sanchez P; Gutierrez X; Sáchez Pina JM; Linares M; Gallardo M; Martinez-López J; Ayala R
Haematologica; 2021 Sep; 106(9):2325-2333. PubMed ID: 32732356
[TBL] [Abstract] [Full Text] [Related]
3. Down-regulation of pseudogene Vimentin 2p is associated with poor outcome in de novo acute myeloid leukemia.
Zhai LL; Zhou J; Zhang J; Tang X; Zhou LY; Yin JY; Vanessa MD; Peng W; Lin J; Deng ZQ
Cancer Biomark; 2017; 18(3):305-312. PubMed ID: 28106537
[TBL] [Abstract] [Full Text] [Related]
4. DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia.
Zhou JD; Zhang TJ; Wang YX; Yang DQ; Yang L; Ma JC; Wen XM; Yang J; Lin J; Qian J
Tumour Biol; 2016 Jul; 37(7):8951-60. PubMed ID: 26753961
[TBL] [Abstract] [Full Text] [Related]
